BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Snoeys J, Beumont M, Monshouwer M, Ouwerkerk-Mahadevan S. Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling. Clin Pharmacokinet 2017;56:781-92. [PMID: 27896690 DOI: 10.1007/s40262-016-0476-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang DZ, Alhadab A, Parivar K, Wang DD, Elmeliegy M. Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations. Clin Pharmacol Ther 2021. [PMID: 34870845 DOI: 10.1002/cpt.2505] [Reference Citation Analysis]
2 El-Khateeb E, Darwich AS, Achour B, Athwal V, Rostami-Hodjegan A. Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment. Aliment Pharmacol Ther 2021;54:388-401. [PMID: 34218453 DOI: 10.1111/apt.16489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Taskar KS, Pilla Reddy V, Burt H, Posada MM, Varma M, Zheng M, Ullah M, Emami Riedmaier A, Umehara KI, Snoeys J, Nakakariya M, Chu X, Beneton M, Chen Y, Huth F, Narayanan R, Mukherjee D, Dixit V, Sugiyama Y, Neuhoff S. Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. Clin Pharmacol Ther 2020;107:1082-115. [PMID: 31628859 DOI: 10.1002/cpt.1693] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
4 Bourgeois S, Horsmans Y, Nevens F, van Vlierberghe H, Moreno C, Beumont M, Vijgen L, van Eygen V, Luo D, Hillewaert V, Van Remoortere P, van de Logt J, Ouwerkerk-Mahadevan S. Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen. Antimicrob Agents Chemother 2017;61:e01217-17. [PMID: 28971875 DOI: 10.1128/AAC.01217-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, Matsson P, Sharma P, Snoeys J, Sugiyama Y, Tatosian D, Unadkat JD, Huang SM, Galetin A; International Transporter Consortium. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clin Pharmacol Ther 2018;104:865-89. [PMID: 30059145 DOI: 10.1002/cpt.1183] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 15.5] [Reference Citation Analysis]